Acute pulmonary embolism (PE) contributes significantly to the global burden of
cardiovascular disease. The severity of the acute PE event determines the expected …

As we step into 2024, the field of pulmonary embolism (PE) research stands at a unique
juncture. Traditional interest concerning venous thromboembolism risk factors and medical …

Introduction Pulmonary embolism (PE) is a life-threatening disease. Risk stratification in
patients with acute PE can guide clinical decisions. Clinical assessment, including …

Venous thromboembolism (VTE), the third most frequent acute cardiovascular syndrome,
may cause life-threatening complications and imposes a substantial socio-economic …

The presentation of acute pulmonary embolism (PE) varies widely, and may range from
absence of symptoms, to cardiogenic shock and sudden death. Consequently, risk …

Hemodynamic instability and right ventricular (RV) dysfunction are the key determinants of
short-term prognosis in patients with acute pulmonary embolism (PE). High-risk PE …

Acute pulmonary embolism (PE) is the third leading cause of death globally, yet the majority
of patients have a low mortality rate and can be treated by anticoagulation alone. 1 …

Acute pulmonary embolism (PE) is one of the major causes of in‑hospital mortality, and the
short‑term prognosis of patients is strongly related to its hemodynamic consequences …

In the assessment and management of patients with acute symptomatic pulmonary
embolism (PE), prognostic information helps to guide therapeutic decision-making. PE is …

Background Real-world data on the impact of advances in risk-adjusted management on the
outcome of patients with pulmonary embolism (PE) are limited. Methods To investigate …